|
End-of-day quote
Taiwan S.E.
2026-10-22
|
5-day change | 1st Jan Change | ||
| 46.15 TWD | -1.49% |
|
-4.35% | -22.18% |
| Market Cap | 5.55B 170M 152M 140M 127M 238M 16.18B 242M 1.69B 668M 8.46B 639M 626M 26.72B | P/E 2024 |
52.9x | P/E 2025 | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 6.67B 205M 182M 169M 153M 286M 19.43B 291M 2.03B 803M 10.16B 768M 752M 32.09B | EV / Sales 2024 |
2x | EV / Sales 2025 | 1.7x |
| Free-Float |
78.86% | Yield 2024 |
4.36% | Yield 2025 | 5.06% |
| 1 day | -1.49% | ||
| 1 week | -4.35% | ||
| Current month | -5.72% | ||
| 1 month | -5.14% | ||
| 3 months | -10.74% | ||
| 6 months | -10.91% | ||
| Current year | -22.18% |
| 1 week | 46.15 |  | 48.25 |
| 1 month | 46.15 | | 49.3 |
| Current year | 45 | | 62.5 |
| 1 year | 45 | | 67.4 |
| 3 years | 45 | | 121 |
| 5 years | 44.2 | | 121 |
| 10 years | 29.75 | | 121 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Yue Cheng
CEO | Chief Executive Officer | - | 1995-12-31 |
Yue Chen Lo
DFI | Director of Finance/CFO | - | 2003-04-13 |
Chin Yuan Lin
IRC | Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Ting Kai Wu
BRD | Director/Board Member | 88 | 2010-05-10 |
Charles Lin
BRD | Director/Board Member | - | 2016-06-27 |
Cheng Yue Cheng
CHM | Chairman | - | 1995-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.49% | -4.35% | -25.56% | -43.79% | 170M | |
| -2.54% | +1.31% | +55.10% | +120.84% | 1,135B | |
| -1.42% | +3.23% | +37.07% | +74.26% | 636B | |
| +0.16% | +0.08% | +25.14% | +97.36% | 505B | |
| -0.31% | +3.09% | +43.92% | +64.55% | 378B | |
| -1.34% | -0.47% | +66.63% | +40.56% | 358B | |
| -0.68% | +2.65% | +22.46% | +51.48% | 295B | |
| -1.20% | +3.04% | +2.62% | +26.97% | 266B | |
| -1.79% | +1.57% | +49.97% | +60.87% | 237B | |
| -0.73% | -0.10% | +29.24% | +101.19% | 193B | |
| Average | -1.13% | +1.52% | +30.66% | +59.43% | 400.45B | |
| Weighted average by Cap. | -1.35% | +2.66% | +40.99% | +82.12% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 4.73B 145M 130M 120M 108M 203M 13.79B 207M 1.44B 570M 7.21B 545M 533M 22.78B | 4.85B 149M 133M 123M 111M 208M 14.14B 212M 1.48B 584M 7.39B 559M 547M 23.36B |
| Net income | 157M 4.83M 4.31M 3.98M 3.61M 6.75M 458M 6.87M 47.88M 18.94M 240M 18.12M 17.73M 757M | 441M 13.54M 12.08M 11.15M 10.11M 18.94M 1.29B 19.26M 134M 53.12M 672M 50.82M 49.74M 2.12B |
| Net Debt | 1.2B 36.72M 32.74M 30.24M 27.42M 51.36M 3.49B 52.23M 364M 144M 1.82B 138M 135M 5.76B | 1.12B 34.25M 30.54M 28.2M 25.58M 47.9M 3.25B 48.71M 340M 134M 1.7B 128M 126M 5.37B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-22 | NT$46.15 | -1.49% | 492,145 |
| 26-10-21 | NT$46.85 | -0.32% | 306,135 |
| 26-10-20 | NT$47.00 | +1.51% | 311,386 |
| 26-10-19 | NT$46.30 | -4.04% | 902,171 |
| 26-10-16 | NT$48.25 | +0.94% | 739,204 |
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4746 Stock
Select your edition
All financial news and data tailored to specific country editions
